Cross-border pollination

Vivo Ventures closes $375M fund, with almost half earmarked for China

Vivo Ventures will invest more in China than ever before with its newly closed, oversubscribed $375 million fund.

The firm's seventh fund was raised in about nine months and had an original target of $350 million. About 40-50% of the money will be invested in therapeutics and medical device companies in China, Managing Partner Edgar Engleman told BioCentury. The remainder will be invested in U.S. companies.

About 20% of the last fund was invested in China. The sixth fund, which closed at $275 million

Read the full 820 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE